Hypertension Clinical Practice Guidelines (CPG) Medical Record Audit (MRA) Report

The CPG Medical Record Audit (MRA) process assesses whether the provider's medical practices conform to clinical standards of practice. The audit tool serves as an instrument to gather information on the use of evidence-based clinical practice guidelines in order to identify the effectiveness, or lack thereof, of the treatment provided in accordance with the guidelines. This audit tool incorporates the standards, established and published by the American College of Cardiology and American Academy of Family Physicians, for the management and treatment of Hypertension.

 $\frac{https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/highbloodpressure.html}{https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/11/09/11/41/2017-guideline-for-high-blood-pressure-in-adults}$

What is a Clinical Practice Guideline?

The IOM in its newest definition describes CPGs as 'statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.' (Consensus report, Institute of Medicine. Clinical practice guidelines we can trust. March 23, 2011)

Purpose of Clinical Practice Guidelines

The intent of clinical practice guidelines are to:

- 1. Improve the quality of patient care and health care outcomes
- 2. Summarizes research findings and make clinical decisions more transparent
- 3. Reduce inappropriate variation in practice
- 4. Promote efficient use of resources
- 5. Identify gaps in knowledge and prioritize research activities
- 6. Provide guidance for consumers and inform and empower patients

Source: Davis D, Joanne G, Palda VA, Handbook on Clinical Practice Guidelines, Canadian Medical Association

The medical records to be audited under the MRA will be selected on a quarterly basis using a true random sample. The actual number of providers audited each quarter will reflect no less than 20% of the total allocated providers within the CMO. The clinical reviewer will randomly select 5 medical records of the selected providers for the review of Hypertension care according to the CPG. The Georgia Families CMOs are required to collaborate to develop a process of equally dividing all providers and assigning each CMO the same group of providers on an annual rotation. Individual CMO should create a review process that: 1) ensures at least 90% of total allocated providers are reviewed by the end of the review year and 2) avoids repeat reviews of any one provider, unless in the event of a reaudit for a previously identified deficit.

The provider's office manager or designee should be notified in advance of the pending MRA. The medical records should be pulled upon the arrival of the reviewer or may be submitted directly to the CMO (paper or electronic version) for review. Reviewers must utilize the DCH-approved forms (see attached) to conduct the audits. All individually identifiable health information must be kept confidential and private by the reviewer, in accordance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and applicable Medicaid laws and regulations. The preliminary results of the audit shall be shared with the provider. Within seven (7) business days of the MRA, formal review findings must be given to the provider's office. Each reviewer/reviewing organization must comply with the DCH approved CPG MRA process when conducting the MRA.

CPG MRA Process:

1. Provider Audit

The CPG Provider Audit Form (Form A) should be completed for each provider selected through the random sample process. Based on the identified indicators, the reviewer should thoroughly evaluate the medical record to determine whether the provider's medical practices conform to the clinical practice guidelines for the particular medical condition. Weights have been assigned to each indicator based on the degree of its importance to the members' overall health outcomes. The weights are calculated to render a weighted rate. (Note: When an indicator is determined to be "not applicable," indicate NA. The assigned weight of that indicator will be credited in calculating total compliance rate).

2. <u>Cumulative Medical Record Audit Report</u>

The Cumulative Medical Record Audit Report (Form B) must be submitted to DCH within 30 days from the end of each quarter. The Cumulative MRA Report is a compilation of the weighted rates calculated for each quarter. The purpose of this document is to inform DCH and the CMOs of the quarterly trends for compliance with this CPG.

3. CPG Quarterly Report

The CPG Quarterly Report (Form C) must be submitted to DCH within 30 days from the end of each quarter. The Quarterly Report, which may be submitted as a Microsoft Word or Excel document, should be completed in accordance with the CPG MRA Specifications.

Rev. 06/2021

Form A - Provider Audit CMO Name: Reporting Period: MM/DD/YYYY-MM/DD/YYYY					YYY							
tysician IDIName: Office Contact: Date of Audit: delenhone: Auditor:												
INDICATORS	ASSES	SMENT TIM	EFRAME	ME	DICAL	RECOF	RDS		Numerator (A)	Denominator (B)	Weights (C)	Weighted Rate (A/B X C) X 100
Match Number to Patient in Confidential Manner	Initial Visit	Follow- Up Visit	Annual Visit	1	2	3	4	5	Total # of charts compliant with indicators	Total # of charts audited	(O)	(AB X G) X 100
Physical Examination											19%	
Documentation of height, weight, and BMI; review of systems, include EENT, skin, growth/pubertal development in children and adolescents at Initial visit, follow-up visit, annual visit as needed	1	*	1								5%	
Documentation of mental/behavioral screening, include depression, anxiety, disordered eating, bullying at initial visit, annual visit or as needed	1		1								3%	
Documentation of co-morbid conditions (e.g. obesity, diabetes) at initial visit, and follow-up visit as indicated	4	4									4%	
Documentation of blood pressure reading or percentile rating, allergies, vital signs, pain, onset, location and intensity of pain; last menstrual period (LMP) as indicated, at Initial visit, follow-up visit, annual visit	4	1	*								7%	
Medical History											10%	
Documentation of Hypertension history (family, characteristics at onset e.g. age, symptoms; abnormal labs or diagnostics, review of previous treatment regimens and responses; assess frequency/cause/severity of past hospitalizations/at Initial visit	4										5%	
Documentation of Personal history of nutritional history, activity level, medication/treatment and psychosocial, If child, documentation of perinatal history)at initial visit, follow-up visit, or annual visit if indicated	1	4	*								5%	
Behavioral Factors											18%	
Documentation that member received education on nutrition/diet/weight management (DASH eating plan, dietary sodium reduction etc.) at initial visit, follow-up visit, or annual visit as needed	4	4	1								6%	
Documentation of interval history, change in physical activity and sleep behaviors at Initial visit, follow-up visit, or annual visit if indicated	1	4	1								8%	
Documentation of tobacco, alcohol, and substance use at Initial visit, follow-up visit, or annual visit if indicated	1	1	*								4%	
Medications and Vaccinations											20%	
Documentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated	1	~	1								7%	
Documentation of evaluated response to treatment/medication therapy regimen and adherence (e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological treatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit	1	1	1								10%	
Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if indicated	1		1								3%	
Education and Referral		<u> </u>									10%	
Education on Blood Pressure Monitoring and/or other education as needed	1	1	1								5%	
Referral to sub-specialty at Initial visit, follow-up visit, or annual visit as indicated.	1	1	*								5%	
Social Life Assessment									1		3%	
Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit	1	1	1								3%	
Laboratory Evaluation									1		20%	
Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit , frequency of testing as indicated by previous findings	1	1	*								5%	
Documentation of serum potassium levels was ordered in patients on "ACEs inhibitors, "*ARBs, or ***diuretics at Initial or annual visit or testing frequency as indicated by previous findings	1	1	1								5%	
Documentation of Lipid profile was ordered including total LDL, HDL cholesterol, and triglycerides at Initial or annual visit or as indicated by previous findings	1	1	*								5%	
Documentation Liver function test was ordered at Initial or annual visit or as indicated by previous findings	1	1	1								5%	
								TC	TAL COMPLIA	ANCE RATE	100%	

Footnote:

#MC & Hypertension Guideline Algorithm: https://thesafo.org/website/wp-content/uploads/2017/05/2014-INC-8-Hypertension pdf
References:

AAPs: https://www.aafo.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/highbloodpressure.html

AARs: https://www.aafo.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/highbloodpressure.html

AARs: https://www.aafo.org/family-physician/patient-care/clinical-recommendations/highbloodpressure.html

AARs: https://www.aafo.org/family-physi

development in children and adolescents at Initial visal, follow-up visal, annual visal as indicated 5% Documentation of mental/behavioral screening, include depression, anxiety, disordered eating, bullying at Initial visal, annual visal or as needed Documentation of Co-morbid conditions (e.g. o-beatty, dislateties) at Initial visal, and follow-up visal as indicated and indi	Indicators	Weights	QUARTER 1 Weighted Rate	QUARTER 2 Weighted Rate	QUARTER 3 Weighted Rate	QUARTER 4 Weighted Rate
Documentation of height, weight, and BMI; review of systems, include EENT, skin, growth/pubertal development in children and adolescents at Initial visit, follow-up visit, annual visit as indicated 5% become that on the production of mentatibehavioral screening, include depression, annual visit as indicated and initial visit annual visit or as needed Documentation of co-morbid conditions (e.g. phealty, diabetes) at milital visit, annual visit as annual visit annual visit annual visit annual visit as annual visit annual v	Phonical Formination	400/				
boultying at initial visit, annual visit or as needed Documentation of co-morbid conditions (e.g. obesity, diabetes) at initial visit, and follow-up visit as indicated or co-morbid conditions (e.g. obesity, diabetes) at initial visit, notation, and intensity of pair; test menstrual period (LMP) as indicated, at initial visit, follow-up visit, annual visit with the condition of blood pressure reading or percentile rating, allergies, vital signs, pain, location, and intensity of pair; test menstrual period (LMP) as indicated, at initial visit, follow-up visit, annual visit with the condition of the personal initial visit, characteristics at onset e.g. e.g., symptoms; abnormal bits or disprostate, review of previous heatment regimens and responses; assess requency/cace/deverty of pair hospitalizationspail relial visit follow-up visit, or annual visit if indicated in the condition of perinatal history) at initial visit, follow-up visit, or annual visit if indicated in the condition of perinatal history, actively level, medication/treatment and psychoscoia (If child, documentation of perinatal history) at initial visit, follow-up visit, or annual visit if indicated in the condition of perinatal history, change in physical activity and sleep behaviors at Initial visit, follow-up visit, or annual visit if indicated in the condition of interval history, change in physical activity and sleep behaviors at Initial visit, follow-up visit, or annual visit if indicated in the condition of interval history, change in physical activity and sleep behaviors at Initial visit, follow-up visit, or annual visit if indicated in the condition of interval history, and the condition of interval history, change in physical activity and sleep behavior annual visit if indicated in the condition of interval history, and the condition of interval history and needs e.g. influenza at Initial visit, follow-up visit, or annual visit if indicated in the condition of interval his	Documentation of height, weight, and BMI; review of systems, include EENT, skin, growth/pubertal development in children and adolescents at Initial visit, follow-up visit, annual visit as indicated					
Indicated Documentation of blood pressure reading or percentile rating, allergies, vital signs, pain, location, and intensity of pain; last menstrual period (LMP) as indicated, at initial visal, follow-up visal, annual visal. Medical History Documentation of Hypertonian history: family, characteristics at naset e.g. age, symptoms; abnormal frequency/cause/eventy of past hospitalizations/jail finitial visal. The requency/cause/eventy of past hospitalizations/jail finitial visal. Documentation of Personal history of nutritional history, activity level, medication/treatment and psychosocial. (If child, documentation of perinatal history) at initial visal, follow-up visal, or annual visal if indicated Behavioral Factors Documentation that member received education on nutrition/dictively fit management (DASH eating plain, dielay socilum reduction etc.) at Initial visal, follow-up visal, or annual visal if annual visal if indicated Documentation of interval history, change in physical activity and sleep behaviors at Initial visal, follow-up visal, or annual visal if indicated Documentation of tobacco, alcohol, and substance use at Initial visal, follow-up visal, or annual visal if indicated Documentation of treatment or medication(s) therapy at Initial visal, follow-up visal, or annual visal if indicated Documentation of evaluated response to treatment/medication interapy regimen and adherence (a.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological retardent, documentation of responses to lifestyle changes/alternate therapy Initial visal, follow-up visal, or annual visal if indicated Documentation of vaccination history and needs e.g. influenza at Initial visal, follow-up visal, or annual visal if indicated Documentation of vaccination history and needs e.g. influenza at Initial visal, follow-up visal, or annual visal if indicated Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify soci	Documentation of mental/behavioral screening, include depression, anxiety, disordered eating, bullying at initial visit, annual visit or as needed	3%				
and intensity of pair; last menstrual period (LMP) as indicated, at Initial visit, follow-up visit, annual visit is the contension of Hypertension history: family, characteristics at onset e.g. age, symptoms; abnormal bas or diagnostics, review of previous frealment regimens and responses; assess frequency/clause/deviewity of pest hospitalizationspit initial visit. Documentation of Personal history of nutritional history, activity level, medication/treatment and psychosocial.(If child, documentation of perinatal history) at mittal visit, follow-up visit, or annual visit if midicated behavioral Factors Documentation of Personal history of nutritional history, activity level, medication/treatment and psychosocial.(If child, documentation of perinatal history) at mital visit, follow-up visit, or annual visit if midicated behaviors at limital visit, follow-up visit, or annual visit if midicated behaviors at limital visit, follow-up visit, or annual visit if midicated behaviors at limital visit, follow-up visit, or annual visit if midicated behaviors at limital visit, follow-up visit, or annual visit if midicated behaviors at limital visit, follow-up visit, or annual visit if midicated behaviors at limital visit, follow-up visit, or annual visit if midicated behaviors at limital visit, follow-up visit, or annual visit if midicated behaviors at limital visit, follow-up visit, or annual visit if midicated behavior, medication intolerance or side effects. If no pharmacological restaurch, documentation of vaccinations to treatment/medication therapy regimen and adherence (e.g., medication-taking behavior, medication intolerance or side effects. If no pharmacological restaurch, documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if midicated behavior annual visit if midicated behavior, medication intolerance or side effects. If no pharmacological restaurch, documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if midicated behavior an	Documentation of co-morbid conditions (e.g. obesity, diabetes) at initial visit, and follow-up visit as indicated	4%				
Documentation of Hypertension history: family, characteristics at onset e.g. age, symptoms; abnormal labs or diagnostics, water of pregimens and responses; assess frequency/cause/severity of past hospitalizationsjat initial visit Documentation of Personal history of nutritional history, activity level, medication/treatment and sponsess observed in the past hospitalizationsjat initial visit, follow-up visit, or annual visit if indicated follow-up visit or annual visit if indicated self-pain, dietary sodium reduction of portinatal history) at initial visit, follow-up visit, or annual visit in diagnosis of interval history, change in physical activity and sleep behaviors at Initial visit. Documentation of Interval history, change in physical activity and sleep behaviors at Initial visit. Documentation of Interval history, change in physical activity and sleep behaviors at Initial visit. Documentation of tobacco, alcohol, and substance use at Initial visit, follow-up visit, or annual visit if indicated do bocumentation of tobacco, alcohol, and substance use at Initial visit, follow-up visit, or annual visit in indicated do bocumentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated do bocumentation of reatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated do bocumentation of evaluated response to Ireatment/medication therapy regimen and adherence (e.g. medication-daking behavior, medication intolerance or side effects. It no pharmacological reatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit in indicated bocumentation of vaccination history and needs e.g. influenza at Initial visit, follow-up visit, or annual visit in indicated bocumentation of sponses to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit in indicated bocumentation of sponses to the past of t	Documentation of blood pressure reading or percentile rating, allergies, vital signs, pain, location, and intensity of pain; last menstrual period (LMP) as indicated, at Initial visit, follow-up visit, annual visit	7%				
Indicated Indi	Medical History	10%				
psychosocial, (if child, documentation of perinatal history) at initial visit, follow-up visit, or annual visit if indicated Behavioral Factors Documentation that member received education on nutrition/diet/weight management (DASH eating plan, dietary sodium reduction etc.) at Initial visit, follow-up visit, or annual visit as needed Documentation of interval history, change in physical activity and sleep behaviors at Initial visit, follow-up visit, or annual visit if indicated Documentation of tobacco, alcohol, and substance use at Initial visit, follow-up visit, or annual visit if midicated Documentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated and treatment or medication indicated and adherence (e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological retartment, documentation of vaccination indicated and ind	Documentation of Hypertension history: family, characteristics at onset e.g. age, symptoms; abnormal labs or diagnostics, review of previous treatment regimens and responses; assess frequency/cause/severity of past hospitalizations)at Initial visit	5%				
Documentation that member received education on nutrition/diet/weight management (DASH eating plan, dietary sodium reduction etc.) at Initial visit, follow-up visit, or annual visit as needed Documentation of interval history, change in physical activity and sleep behaviors at Initial visit. Rollow-up visit, or annual visit if indicated Documentation of tobacco, alcohol, and substance use at Initial visit, follow-up visit, or annual visit if indicated Medications and Vaccinations Documentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated or annual visit or annual visit as indicated or annual visit or annual visit as indicated or annual visit or annual visit or annual visit as indicated or annual visit or annual	Documentation of Personal history of nutritional history, activity level, medication/treatment and psychosocial.(If child, documentation of perinatal history)at initial visit, follow-up visit, or annual visit if indicated	5%				
Documentation of interval history, change in physical activity and sleep behaviors at Initial visit, follow-up visit or annual visit in indicated Documentation of tobacco, alcohol, and substance use at Initial visit, follow-up visit, or annual visit in indicated Medications and Vaccinations Documentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit in indicated Documentation of evaluated response to treatment/medication therapy regimen and adherence (e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological treatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit in annual visit in inclicated Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if indicated Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if indicated Education and Referral Education on Blood Pressure Monitoring and/or other education as needed Social Life Assessment 3% Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit, frequency of lesting as indicated by previous findings	Behavioral Factors	18%				
Documentation of tobacco, alcohol, and substance use at Initial visit, follow-up visit, or annual visit if Indicated Medications and Vaccinations Documentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated Documentation of evaluated response to treatment/medication therapy regimen and adherence (e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological treatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit if Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if Indicated Education and Referral Education on Blood Pressure Monitoring and/or other education as needed Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Documentation that member received education on nutrition/diet/weight management (DASH eating plan, dietary sodium reduction etc.) at Initial visit, follow-up visit, or annual visit as needed	6%				
Medications and Vaccinations Documentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated procumentation of evaluated response to treatment/medication therapy regimen and adherence (e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological treatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit or annual visit Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if indicated Education and Referral Education and Referral Education on Blood Pressure Monitoring and/or other education as needed Referral to sub-specialty at Initial visit, follow-up visit, or annual visit as indicated. Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Documentation of interval history, change in physical activity and sleep behaviors at Initial visit, follow-up visit, or annual visit if indicated	8%				
Medications and Vaccinations Documentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated Documentation of evaluated response to treatment/medication therapy regimen and adherence (e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological treatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if indicated Education and Referral Education on Blood Pressure Monitoring and/or other education as needed Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings		4%				
Documentation of evaluated response to treatment/medication therapy regimen and adherence (e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological treatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if indicated Education and Referral Education on Blood Pressure Monitoring and/or other education as needed 5% Referral to sub-specialty at Initial visit, follow-up visit, or annual visit as indicated. 5% Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Medications and Vaccinations	20%				
(e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological treatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit if indicated Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if 3% Education and Referral 10% Education on Blood Pressure Monitoring and/or other education as needed 5% Referral to sub-specialty at Initial visit, follow-up visit, or annual visit as indicated. 5% Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Documentation of treatment or medication(s) therapy at Initial visit, follow-up visit, or annual visit as indicated	7%				
Education and Referral Education and Referral 10% Education on Blood Pressure Monitoring and/or other education as needed 5% Referral to sub-specialty at Initial visit, follow-up visit, or annual visit as indicated. 5% Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Documentation of evaluated response to treatment/medication therapy regimen and adherence (e.g. medication-taking behavior, medication intolerance or side effects. If no pharmacological treatment, documentation of response to lifestyle changes/alternate therapy Initial visit, follow-up visit, or annual visit	10%				
Education on Blood Pressure Monitoring and/or other education as needed Referral to sub-specialty at Initial visit, follow-up visit, or annual visit as indicated. 5% Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Documentation of vaccination history and needs e.g. influenza at Initial visit, or annual visit if indicated	3%				
Referral to sub-specialty at Initial visit, follow-up visit, or annual visit as indicated. 5% Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Education and Referral	10%				
Social Life Assessment Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Education on Blood Pressure Monitoring and/or other education as needed	5%				
Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit 20% Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Referral to sub-specialty at Initial visit, follow-up visit, or annual visit as indicated.	5%				
advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit Laboratory Evaluation 20% Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Social Life Assessment	3%				
Documentation of lab tests: glucose, urinallysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit, frequency of testing as indicated by previous findings	Documentation of Social network (e.g. existing social supports, identify surrogate decision maker, advanced care plan, identify social determinations of health) at Initial visit, follow-up visit, or annual visit	3%				
glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit , frequency of testing as indicated by previous findings	Laboratory Evaluation	20%				
	Documentation of lab tests: glucose, urinalysis, sodium, potassium, serum creatinine & estimated glomerular filtration rate (eGFR) other renal panel tests not listed here, at Initial, annual visit , frequency of testing as indicated by previous findings	5%				
Documentation of serum potassium levels was ordered in patients on *ACEs inhibitors, **ARBs, or ***diuretics at Initial or annual visit or testing frequency as indicated by previous findings	Documentation of serum potassium levels was ordered in patients on *ACEs inhibitors, **ARBs, or ****diuretics at Initial or annual visit or testing frequency as indicated by previous findings	5%				
	Documentation of Lipid profile was ordered including total LDL, HDL cholesterol, and triglycerides at Initial or annual visit or as indicated by previous findings	5%				
	Documentation for Liver function test was ordered at Initial or annual visit or as indicated by previous findings	5%				
100%		100%				

Hypertension CPG Medical Record Audit Report Specification for Quarterly Report

(m	ay submit report as Microso	oft Word or Excel document)				
	DO NOT	MODIFY				
Report Name	CPG Medical Record	Audit (MRA) Quarterly Report				
CMO Name	Enter name of CMO					
Report Date	Enter report date as MM/DD/YYYY					
Frequency	Submit report quarter	ly				
	CPG Claims	Date of Review	Report Due			
	Jan 1- Mar 31	Apr 1- Jun 30	July 31			
Reporting Period	Apr 1- Jun 30	Jul 1- Sept 30	Oct 31			
	Jul 1- Sept 30	Oct 1- Dec 31	Jan 31			
	Oct 1- Dec 31	Jan 1- Mar 31	April 30			
FIELD	FIELD DESCR	IPTION				
Total Number of Records Reviewed	Hypertension. Enter total number of (Transfer number from A	records reviewed this quarter Form B: Summarized MRA)	etice guideline (CPG) for			
Compliance Rate (%)	Enter compliance percentage rate for this quarter. (Transfer % rate from Form B: Summarized MRA)					
Total Number of Providers Reviewed	Enter total number of providers reviewed this quarter. (Transfer % rate from Form B: Summarized MRA)					
Total Number of Providers by Type	Using the "Total Number of Providers Reviewed" for this quarter, enter the total number of providers for each of the following categories: Family Medicine, Internal Medicine, Pediatrician, NP/PA, Behavioral Health, Specialist Acting as PCP or Other."					
Quarterly Summary of Top 3 Providers Audit Deficits	Review office deficits as indicated on Form A: Provider Audit. Enter the top 3 deficiency areas in the numbered cells.					
Number of Provider Sites with this deficit	For each of the Top 3 deficiencies listed, enter the total number of provider sites for each deficiency. A deficiency occurs if a provider scores a total compliance rate of less than eighty percent (80%).					
Deficits Outcome	Provider Focused Review: for providers with deficits in the same CPG for two or more audited records, provide feedback and re-audit for initial CPG if deficits are identified from the re-audit, provide coaching by supervising clinician or designee of equal or higher clinical practice, and re-audit. If no deficits at second re-audit, no further action is needed. For deficits beyond second re-audit, consider continuing education, or provide proctoring. CMOs will complete a Corrective Action Plan(CAP) for providers with persistent deficiencies. System Focused Review: if total number of providers with deficit in any of the top three deficits is equal to or more than 20% of total reviewed providers for the quarter, CMOs will audit additional 10 randomly selected records per related CPG. If evidence of deficit, provide system wide provider education. Re-audit the following quarter. If deficit falls below threshold, no further action is required. If deficit persists, identify offending providers and initiate Provider Focused Review. For persistent system wide deficiencies, the CMOs will complete a Corrective Action Plan (CAP) for providers.					

ider ' Review		Quarterly Summary of Top 3 Office Review Deficits (Place top 3 areas in numbered cells.)
rov ary	\searrow	
	2	
Su	3	

Number of Providers with this deficit	Focus Review	Review Type
	Yes/No	
	Yes/No	
	Yes/No	

9	s Clinical Practice Guidelines quarterly reports, as portal. Graphs, charts, and other documentation
I,	, do hereby attest that the above
information is true and correct to the	<u> </u>
Date:	

This form must be reviewed, signed, and dated by the CMO's Chief Medical Officer and